Efficacy News and Research

RSS

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Guidelines needed for the use of androgens for women with sexual dysfunction

The Endocrine Society, which represents more than 12,000 endocrinologists who are specially trained to diagnose, treat and conduct basic and clinical research on complex hormonal disorders, has called for new clinical guidelines on the use of androgens in women/female sexual dysfunction.

3 Dec 2004

Smoking habits during pregnancy may cause genetic instability in the foetus

The Spanish Pediatrics Association has recently awarded the Pediatrics laboratory at the University of Navarre for a research into tobacco and foetal genetic instability.

2 Dec 2004

Higher incidence of rejection following early steroid withdrawal

A new study on early steroid withdrawal following liver transplantation found that there was a higher incidence of rejection and a lower incidence of glucose intolerance necessitating treatment for diabetes.

1 Dec 2004

World Health Organization is reinstating two antiretrovirals manufactured by Cipla Ltd

The two medicines (which are used in the treatment of AIDS) had been delisted by WHO in May this year due to non-compliance with international standards at the contract research organizations (CROs) hired by Cipla to conduct bioequivalence tests on the products.

30 Nov 2004

Adding a commonly used dietary supplement to antidepressants may improve treatment

Massachusetts General Hospital (MGH) researchers have found that adding the nutritional supplement SAMe to a standard antidepressant may be helpful to patients who have not responded to single-drug treatment for clinical depression.

30 Nov 2004

Viral Genetics announces effects of VGV-1 in antiretroviral non-responding HIV infections

Viral Genetics announced today that the results of a clinical trial of its investigational therapy for HIV infection, VGV-1, were recently published in a peer reviewed journal, HIV & AIDS Review.

29 Nov 2004

Drug combination of amodiaquine and sulfadoxinepyrimethamine might offer the optimal treatment for malaria

Results of a randomised trial from Uganda in this week’s issue of THE LANCET suggest that the drug combination of amodiaquine and sulfadoxinepyrimethamine might offer the optimal treatment for malaria in terms of efficacy and cost-effectiveness in this region.

29 Nov 2004

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

Forest Laboratories have announced that Combunox (Oxycodone HCl and Ibuprofen) Tablets (CII), the first and only fixed-dose combination of the opioid oxycodone HCl (5 mg) and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (400 mg), was approved by the U.S. Food and Drug Administration (FDA) for the short-term management of acute, moderate to severe pain.

29 Nov 2004

U.S. pharmacists not opposed to importing drugs to lower patients' costs

Many community pharmacists are not opposed to importing drugs to lower patients' costs as long as those drugs are channeled through U.S. pharmacies to ensure safety and efficacy, according to a study by pharmacists at the University of Illinois at Chicago and the University of Michigan.

24 Nov 2004

Stem cells derived from umbilical cords are a viable and effective transplant source for thousands of leukemia patients

A new study published in the New England Journal of Medicine confirms that stem cells derived from the umbilical cords of newborn babies are a viable and effective transplant source for thousands of leukemia patients who have no other treatment option.

24 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Low-dose antioxidant supplementation may reduce the risk of cancer among men, but not in women

According to the article, antioxidants including beta carotene, ascorbic acid, vitamin E, selenium, and zinc may prevent some of the harmful effects caused by free radicals – reactive molecules produced by metabolism in the body.

23 Nov 2004

Hetero Drugs withdraws antiretrovirals

Following an inspection by the World Health Organization (WHO), generic manufacturer Hetero Drugs Limited, in Hyderbad, India, is withdrawing six antiretrovirals from the WHO prequalification list in order to review data on their bioequivalence.

20 Nov 2004

AstraZeneca reconfirms the safety of Crestor

In the case of Crestor (rosuvastatin calcium), the application for approval was the most extensive ever for a statin involving more than 12,000 patients, and was unanimously recommended for approval by the FDA's advisory board in July of 2003.

20 Nov 2004

Capsules may be effective in treating bipolar disorder

University of North Carolina at Chapel Hill researchers have announced study results finding that a formulation of three-beaded extended-release carbamazepine capsules (ERC-CBZ) was effective, safe and tolerable in the treatment of bipolar I disorder

19 Nov 2004

FDA Vioxx fiasco raises questions about AIDS drug approvals for developing world

AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.

19 Nov 2004

Efficacy News and Research

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

A new treatment for patients with chronic myeloid leukemia

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Single dose phase I data on CG53135 for the prevention of oral mucositis

Guidelines needed for the use of androgens for women with sexual dysfunction

Smoking habits during pregnancy may cause genetic instability in the foetus

Higher incidence of rejection following early steroid withdrawal

World Health Organization is reinstating two antiretrovirals manufactured by Cipla Ltd

Adding a commonly used dietary supplement to antidepressants may improve treatment

Viral Genetics announces effects of VGV-1 in antiretroviral non-responding HIV infections

Drug combination of amodiaquine and sulfadoxinepyrimethamine might offer the optimal treatment for malaria

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

U.S. pharmacists not opposed to importing drugs to lower patients' costs

Stem cells derived from umbilical cords are a viable and effective transplant source for thousands of leukemia patients

FDA approval of Tysabri, for the treatment of multiple sclerosis

Low-dose antioxidant supplementation may reduce the risk of cancer among men, but not in women

Hetero Drugs withdraws antiretrovirals

AstraZeneca reconfirms the safety of Crestor

Capsules may be effective in treating bipolar disorder

FDA Vioxx fiasco raises questions about AIDS drug approvals for developing world

One Health, One Mission: The World Organisation for Animal Health on the AMR Frontline

Uniting Against Resistance: The World Health Organization for World Antimicrobial Awareness Week 2023

Tackling Antimicrobial Resistance: A Conversation with Dr. Beverley Isherwood

Latest News